✦ LIBER ✦

5-HT 3 Receptor Partial Agonist Modulation, a Novel Approach to the Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

✍ Scribed by Manning, David ;Wierschke, Jonathan D. ;Barnes, Nicholas M. ;Moore, Nicholas

Book ID: 122198013
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 133 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(11)62547-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Orally Active Benzoxazole Derivative as

Orally Active Benzoxazole Derivative as 5-HT 3 Receptor Partial Agonist for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

✍ Yoshida, Satoshi; Shiokawa, Sojiro; Kawano, Ken-ichi; Ito, Tomoko; Murakami, Hir 📂 Article 📅 2005 🏛 American Chemical Society 🌐 English ⚖ 88 KB

Partial Agonism of 5-HT 3 Receptors: A N

Partial Agonism of 5-HT 3 Receptors: A Novel Approach to the Symptomatic Treatment of IBS-D

✍ Moore, Nicholas A.; Sargent, Bruce J.; Manning, David D.; Guzzo, Peter R. 📂 Article 📅 2012 🏛 American Chemical Society 🌐 English ⚖ 362 KB

ChemInform Abstract: Design and Synthesi

ChemInform Abstract: Design and Synthesis of Piperazinylpyridine Derivatives as Novel 5-HT1A Agonists/5-HT3 Antagonists for the Treatment of Irritable Bowel Syndrome (IBS).

✍ Akira Asagarasu; Teruaki Matsui; Hiroyuki Hayashi; Satoru Tamaoki; Yukinao Yamau 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 15 KB 👁 2 views

Novel serotonin type 3 receptor partial

Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome

✍ David D. Manning; Christopher L. Cioffi; Alexander Usyatinsky; Kevin Fitzpatrick 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 474 KB

Serotonin type 3 (5-HT(3)) receptor partial agonists are being targeted as potential new drugs for the treatment of irritable bowel syndrome (IBS). Two new chemical series bearing indazole and indole cores have exhibited nanomolar binding affinity for the h5-HT(3)A receptor. A range of partial agoni

377 A Randomized, Double-Blind, Placebo-

377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS)

✍ William G. Paterson; Jonathon Springer; Michael O'Mahony; Richard P. Reynolds; S 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 95 KB